Cite
HARVARD Citation
Levin, M. et al. (2023). AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019. Clinical infectious diseases. pp. 1247-1256. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Levin, M. et al. (2023). AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019. Clinical infectious diseases. pp. 1247-1256. [Online].